Molecular imaging | GE Healthcare

Discovery comes in many forms. It can be a novel insight into an old problem, or an unexpected revelationafter a long journey. And while every discovery is inspired by the search for something new, what molecular imaging enablesis different. Molecular imaging seeks deeper truths evidence of what is seen, and often not.

This discovery could save the life of one of the patients you see every day in your community hospital, or it could transcendan individual to benefit all patients.

This is known as true discovery.

With its focus on exploration at the molecular and cellular levels, molecular imaging is ideally suited for finding deeplyhidden truths. Each component of the molecular imaging workflow, from acquisition to reconstruction to report generationand communication with referring physicians, is integral to this mission.

As your technology partner, were driven to optimizing each of these components to provide you with the outcomes-basedsolutions you require. We accomplish this by following three core principles. First, we apply an interconnected developmentprocess that offers a comprehensive solution. Then, we emphasize the importance of accurate quantitation. And lastly,we work towards our vision for a fully digital molecular imaging experience.

A fully digital experience connects and enhances each step of the molecular imaging workflow. It starts with best-in-classhardware and software that collects all of your data in the cloud. Then, through deep learning and analytics, that datacan be converted into actionable insights to advance your clinical, operational and economic outcomes.

The beauty of innovation is that its ever-evolving. What makes our vision for a fully digital molecular imagingexperience so exciting is that its a journey we can take together. You can start experiencing its benefits today,while we continue to strive toward the full value of digital technology.

To help you get the most out of your technology, we can be adaptable to your needs. We want you to choose the system thatsright for you, knowing that every system is designed to leverage our fully digital vision right away. It may be a systemalready fitted with digital detection technology, or it may be an adaptable, digital-detection-ready system. No matterwhat you choose, it has the software and hardware needed to start delivering the analytics for operations optimizationand better protocol, patient and asset management.

Get ready. The time for true discovery is now.

Originally posted here:

Molecular imaging | GE Healthcare

Faculty Research – Department of Molecular Medicine …

Rong Li, Ph.D.

Professor

Profile and Contact Information | Research | Laboratory

RESEARCH

Our laboratory addresses the following three fundamental questions concerning breast cancer treatment and prevention.

1. How does BRCA1 suppress tumor development in a gender- and tissue-specific manner? Women who carry cancer-predisposing germ-line mutations in BRCA1 have significantly increased chance of developing breast and ovarian cancers. While the BRCA1 activity in DNA repair is clearly important to the etiology of BRCA1-associated cancers, it is not clear whether the DNA repair function alone is sufficient to account for the gender- and tissue-specific tumor suppression by BRCA1. We previously identified a BRCA1-binding protein COBRA1, which is identical to the B subunit of NELF involved in pausing of RNA polymerase II. Using mouse genetics and clinical samples from BRCA1 mutation carriers, we are investigating whether a crosstalk between BRCA1 and COBRA1-regulated transcription machinery contributes to the tissue-specific function of BRCA1 in breast epithelium.

2. How can the antitumor activity of estrogen receptor (ER) be mobilized?In contrast to the tumor-promoting activity of ER, ER inhibits tumor growth in breast cancer. Because ER is present in a significant percentage of breast cancer cases, rallying its antitumor activity could serve as a potential therapeutic approach. Our pioneer discovery of a phosphotyrosine switch for the antitumor activity of ER enables us to mobilize ER function with unprecedented precision. We are testing the hypothesis that turning on this molecular switch of ER can inhibit triple negative breast cancer and circumvent hormonal resistance of ER-positive breast cancer, two clinically pressing areas where therapeutic potential of ER has been previously demonstrated.

3. How do adipose stromal cells (ASC) promote breast cancer progression?ASC is a major constituent of the breast and a source of tumor-promoting factors including estrogens. We recently discovered a new mechano-transducing pathway that links mechanical phenotype with the endocrine/paracrine output of ASCs. This pathway is initiated by a cell surface receptor called discoidin domain receptor 1 (DDR1). Combining three-dimension cell culture systems and animal models, we are exploring novel therapeutic approaches to disrupt this stroma-tumor communication.

Selected Publications

Complete list of published work.

Read more:

Faculty Research - Department of Molecular Medicine ...

Nuclear Medicine – Molecular Imaging – Nuclear Medicine …

TRUE DISCOVERY AWAITS

It takes a certain mind to go in search of true discovery. In nuclear medicine, they are the clinical researchers looking to set new standards of care, the practitioners working to deliver better outcomes for the patients they see every day and the cardiologists seeking a better understanding of the heart. While they all have the same goal, their needs are different and cant all be met with one system or technology.

Nuclear medicine is an excellent choice for physicians at the forefront of medicine. It has a wide range of available radioisotopes with various energy emission levels and longer half-lives. It also has the flexibility to explore multiple pathways in a single session. These are some of the reasons why we made a commitment to realizing the full potential of and growing this modality.

This commitment involves making nuclear medicine technology more accessible and enabling it to provide results that are more valuable to referring physicians. It means driving down daily operational costs and innovating in four key areas: image quality, dose reduction, exam speeds and quantitative applications. All with the end result of enabling better clinical and economic outcomes.

It also includes our vision for a fully digital nuclear medicine experience. An experience that starts with best-in-class hardware and software that collects your data in the cloud and then converts that data into actionable insights through deep learning and analytics. All of our systems are designed to leverage this fully digital vision right away. If you are interested in digital detection technology as well, you can choose between a system already fitted with CZT-based digital detectors or an adaptable, digital-detection-ready system.

No matter what nuclear medicine technology you choose, you will have the tools you need to go in search of true discovery.

Accurate quantitation

High image quality

Short exams

Dose efficiency

Expanded access

Fully digital experience

See more here:

Nuclear Medicine - Molecular Imaging - Nuclear Medicine ...

Molecular Medicine Research – Wake Forest School of Medicine

The Section on Molecular Medicinefocuses on performing cutting-edge research in cellular and molecularmechanisms of human disease and supports graduate and postgraduate leveleducational programs within the Department of Internal Medicine. The Sectionserves as the administrative home for the largest PhD graduate program(Molecular Medicine and Translational Science) in the Biomedical Sciences atWake Forest University and an NIH-sponsored institutional predoctoral trainingprogram (T-32) in Integrative Lipid Sciences, Inflammation, and ChronicDiseases.

A major goal of the section is toserve as a nidus for translational research by providing an environment whereclinical and basic science faculty interact to make new discoveries and toeducate future scientists.

The section consists of ten (10) primary faculty members and one (1) Emeritus faculty member who use cellular and molecular approaches to gain abetter understanding of the basic mechanisms underlying several chronic humanconditions including: asthma, atherosclerosis, hepatosteatosis, obesity andinsulin resistance, autoimmunity, and age-related pathology (arthritis,Alzheimers disease).

A particular research focus isthe role of inflammation in the pathogenesis of acute and chronic humandiseases. Faculty research strengths are in areas of cell signaling, cellbiology, proteomics, regulation of gene expression, and the use of genetically-modifiedmouse models of human disease. The research in the section is supported bygrants from the NIH, from the Department of Defense, from foundations including the Avon Foundation and theAmerican Heart Association, and from partnerships with industry.

The section also provides acenter for laboratory research training and education in translational researchfor medical students, residents, and postdoctoral fellows includingsubspecialty fellows in the Department of Internal Medicine. A seminar seriesis held weekly in conjunction with the graduate program in Molecular Medicineand Translation Science.

John S. Parks, PhDProfessor of Internal Medicine, Biochemistry, and Translational ScienceChief, Section on Molecular Medicine

Molecular Medicine Journal Club

Faculty News

See the rest here:

Molecular Medicine Research - Wake Forest School of Medicine

MH-Hannover: MD/PhD Program "Molecular Medicine"

Fully accreditated in 2009 as the first PhD program in Germany according to European standards (ECTS), the Hannover Biomedical Research School features an interdisciplinary curriculum leading to a PhD thesis after 3 years.

The program is a joint venture between thefollowing institutions:# Hannover Medical School# TheUniversity of Veterinary Medicine Hannover# The Leibniz UniversittHannover# TheFraunhofer Institute ITEM Hannover# The FriedrichLffler Institute Mariensee# The Helmholtz Centre for Infection Research (HZI) Braunschweig # TwinCore (Hannover)

PhD topicscover abroad spectrum, including the following areas:# Immunology & Infection# Molecular & Cell Biology# Hematology & Oncology# Biochemistry & Structural Biology# Genetics# Stem Cell Research

Potential PhD students: Holders of an M.Sc. or equivalent degree in Medicine,Veterinary Medicine, Biology, Biochemistry, Biotechnologyor Molecular Biology.

Medical students/graduates are invited to check MD/PhD education for more clinical training options. Please note that we only award a PhD title (not an "MD/PhD")

What we offer: In-depth basic science seminars for the first two years. And all are welcome to attend lectures of the Biomedicine or Biochemistry Master programmes.

Next application deadline: April 1st, 2018. Online application from December1st 2017 at http://www.hbrs-application.de

See the original post:

MH-Hannover: MD/PhD Program "Molecular Medicine"

Master of Science (MSc) in Molecular Medicine – NTNU

The field of molecular medicine is often referred to as "tomorrow's medicine". It aims to provide a molecular understanding of how normal cellular processes change, fail or are destroyed by disease. The purpose of the MSc programme is to develop knowledge and skills in cellular and molecular biology. These have applications in both research and practical clinical work, and will contribute to an increased understanding of processes, diagnostics and treatment of diseases.

The application deadline for for applicants from non-EU/non-EEA students is 1 December. The application deadline for students from EU/EEA countries is 1 March. You submit your application electronically.

The MSc in Molecular Medicine qualifies graduates for a wide range of careers, including practical clinical work and technical executive positions in hospital laboratories, and positions in pharmaceuticals and MedTech/BioTech companies.

The MSc is a two-year, full-time programme starting in the autumn semester. There are two main components: a master's thesis worth 60 credits, and theoretical and methodological courses totalling a further 60 credits.

Contact one of our student counsellors if you have any questions about the MSc programme. Email: studie@ikom.ntnu.no/ Telephone: +47 72 82 07 00

See more here:

Master of Science (MSc) in Molecular Medicine - NTNU

Molecular Medicine Journals | Peer Reviewed | Open Access

Journal of Molecular Medicine and Therapy(JMMT), a newly launched journal which will be dedicated to advancing the science and practice of molecular medicine through the rapid publication of high-quality original research, systematic reviews, meta-analyses and technology reports, perspectives on all disciplines and therapeutic areas within the specialty.

The mission of Journal of Molecular Medicine and Therapy(JMMT) is to provide readers with a broad spectrum of themes in molecular medicine and therapy. The principal criterion for publication is potential impact on patient care.

Aims and Scope

Journal of Molecular Medicine and Therapy(JMMT) is an open access journal designed for the wide dissemination of research in this field to worldwide audience. New developments in methodology and techniques are important resources for the research community.

With an emphasis on conceptual breakthroughs, its goal is to facilitate rapid publication and circulation of novel discoveries in the field of molecular and clinical research, molecular immunology, molecular pathology, molecular genetics, molecular human genomics, molecular microbiology, molecular pathogenesis, molecular cardiology, molecular surgery and molecular psychology. It features original research, review articles, clinical cases, perspective, commentary and others.

You may submit manuscripts through online at http://www.editorialmanager.com/alliedjournals/ oras an E-mail attachment to[emailprotected]

Individuals interested in becoming members of the Editorial Review Board should contact by below email.

The rest is here:

Molecular Medicine Journals | Peer Reviewed | Open Access

Molecular and Cellular Pharmacology Training Program …

The Molecular and Cellular Pharmacology Graduate Program at the University of Wisconsin-Madison is ranked in the top Pharmacology programs nationwide, reflecting the outstanding teaching and research quality of its members. The program is based in the Basic Science Departments of the University of Wisconsin School of Medicine and Public Health.

The objective of the Molecular and Cellular Pharmacology Training Program is to equip students with the skills required to conduct high impact biomolecular, biomedical, and pharmacological basic research. The program assists students in becoming independent investigators in these research areas.

Advances in biomedical sciences are often based on the development of new drugs which improve and save the lives of millions of patients. Drugs with specific biochemical actions are also powerful research tools. They provide pharmacologists and other biomedical scientists unique research opportunities which help to elucidate cellular signaling cascades. Students of the program will develop expertise in the fundamentals of Molecular and Cellular Pharmacology. They will be able to solve a variety of problems in basic biomedical sciences involving the design of research strategies for the discovery of novel drugs or gene therapy approaches.

Continue reading here:

Molecular and Cellular Pharmacology Training Program ...

Molecular Medicine | University of Maryland School of Medicine

The Graduate Program in Molecular Medicine at the University of Maryland Baltimore offers research and training opportunities with internationally-renowned scientists. Our Molecular Medicine Program is an interdisciplinary program of study leading to a Ph.D. degree. There are four different research tracks: Cancer Biology, Genome Biology, Molecular and Cell Physiology, and Toxicology and Pharmacology. Each provides for a unique interdisciplinary research and graduate training experience that is ideally suited for developing scientists of the post-genomic era.

Faculty mentors in this graduate program are leaders in their respective research areas and reside in various departments and Organized Research Centers in the School of Medicine and Dental School, the Institute for Genomic Sciences (IGS), the Institute of Human Virology (IHV), the Marlene and Stewart Greenebaum Cancer Center, and the Center for Vascular and Inflammatory Diseases (CVID). The over 150 faculty in the Graduate Program in Molecular Medicine are internationally recognized for their research in biotechnology, cancer, cardiovascular and renal biology, functional genomics and genetics, membrane biology, muscle biology, neuroscience and neurotoxicology, reproduction and vascular biology.

More:

Molecular Medicine | University of Maryland School of Medicine

Home – Weatherall Institute of Molecular Medicine

The mission of the MRC Weatherall Institute of Molecular Medicine (WIMM) is to undertake internationally competitive research into the processes underlying normal cell and molecular biology and to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases. It is also our mission to translate this research to improve human health. The WIMM is uniquely placed among biomedical institutes throughout the world in its pioneering vision of combining outstanding clinical research with excellent basic science. The WIMM Faculty currently includes an equal mixture of scientists and clinicians working together and in collaboration with the National Institute of Health Research, the NHS and commercial companies with the aim of improving the diagnosis and treatment of human diseases. The major topics of current research include haematology, immunology, stem cell biology, oncology and inherited human genetic diseases. The Institute benefits from strategic support from the MRC.

The Institute values communication with members of the broader scientific community and the general public and with the support of the Medical Research Council (MRC) we have commissioned three short videos to explain our mission.

Researchers from RDM kick off a week-long science extravaganza today at The Royal Society Summer Science Exhibition. The team will be exhibiting a unique blend of genetics and virtual reality on their stand, DNA Origami: How do you fold a genome? The team are one of 22 exhibits at the festival a celebration of science and innovation. They will be taking visitors through the intricate world of DNA folding, using virtual reality and ...

We are delighted to announce that Prof Sir David Weatherall has been awarded a GBE, making him a Knight of the Grand Cross. This is the highest rank in the Order of the British Empire and the honour has only been bestowed 16 times since 2000. Prof Sir Weatherall was recognised for his services for medicine and it is wonderful that his pioneering work and commitment to molecular medicine have been recognised in this way. David Weatherall is a ...

News Archive

Applications are invited for a highly motivated professional seeking to develop a career in Health and Safety in a medical research setting. The Deputy Safety Officer will join a small team of core staff who look after the day-to-day management of the Institute. Working closely with the Institutes Safety Officer you will have the personal drive and initiative to advise, manage and report on all aspects of health and safety for the Institute. ...

Other Vacancies

Viruses are basically packets of nucleic acid, DNA or its sister molecule RNA. Our cells have therefore evolved to recognise these molecules as a sign of virus infection. A recent study from Jan Rehwinkels lab in the MRC Human Immunology Unit has revealed a new way in which cells sense and respond to invading viruses. Layal Liverpool, a DPhil student in the Rehwinkel lab, who was involved in the work, explains more.

WIMM Blog Archive

Original post:

Home - Weatherall Institute of Molecular Medicine

Donated bodies benefit UA medical students – Green Valley News

As we near the end of life, we start thinking about where wed like our treasures to go: a favorite quilt, jewelry, maybe some art work. Some people take it a step further: Last year, 400 people left their bodies to the University of Arizona.

The UA's College of Medicine, Department of Cellular & Molecular Medicine created the Willed Body Program 50 years ago so future doctors could learn anatomy from someplace other than textbooks.

Every year, more than 120 first-year medical students from the UA visit the anatomy lab to learn lessons about the thorax, digestive system, neuroscience or the reproductive or life cycle system, said Dr. Jean Wilson, professor of Cellular and Molecular Medicine and director of the Willed Body Program. Residents and fourth-year medical students also have access to the lab so they can focus on their specialized fields.

The students also learn about biochemistry and the impact pharmacology can have on the body, Wilson said.

For students to be able to do a dissection on a whole body is unparalleled for two reasons, she said. First, it allows them to understand the common themes of the human body, but more importantly, it allows them to see all of the variations, and there are many, many variables in the human body. Being able to see the variations allows them to become better doctors.

For example, Wilson said blood vessels can split many different ways besides the textbook way, even within the same body. Theres a particular back muscle that is only present in 25 percent of people and the duct system of peoples gall bladders vary widely, too.

Typically, four to six students will work at one table, but they are encouraged to look at what the other students in their class are doing as well, Wilson said.

On Friday, medical students from the Class of 2020 held a Memorial Service to honor those who donated their bodies through the Willed Body Program. Students and staff spoke about the anonymous donors and how they wonder what they were like in life, especially as they notice their ailments or touch their hearts and hold their hands. They marveled at their willingness to provide such an invaluable gift, describing them as selfless.

They also talked about how the lessons they learned from their donors will be applied in the future and how theyll never forget them.

Medical school is much different than it used to be, Wilson said.

It used to be 30, 40, 50 years ago, med students came in, did their gross-anatomy class and, unless they were going to become a surgeon, it would be the last time theyd see inside a body, Wilson said.

Nowadays, thanks to the various imaging systems, all doctors can see whats going on in the human body and so their gross anatomy lessons are more relevant than ever, Wilson said.

Wilson stressed the program is more than anatomy. It provides life lessons.

It also helps the students confront death, sometimes for the first time, Wilson said.

There are a few restrictions to participating in the program, but for the most part, donors must be 18 or older, live in Arizona at least part-time and be enrolled in the program. The program only accepts donors if they die in-state and transportation costs are covered by the Willed Body Program. If a funeral home must be used, all costs associated with services, storage and transportation by the funeral home are the responsibility of the family.

The UA also shares donations with Arizona State University and Northern Arizona University, Wilson said.

The success of our program depends on people who are willing to donate, Wilson said. Weve been really lucky with the number of donors, but we can never predict the future, so we never discourage anyone from donating.

Original post:

Donated bodies benefit UA medical students - Green Valley News

‘Shapeshifter’ that regulates blood clotting is visually captured for the first time – Bioscience Technology

We are normally born with a highly sophisticated array of molecules that act as "sentries," constantly scanning our bodies for injuries such as cuts and bruises. One such molecular sentry, known as von Willebrand factor (VWF), plays a critical role in our body's ability to stop bleeding.

To prevent hemorrhage or life-threatening blood clots, VWF must strike a delicate balance between clotting too little or too much. Researchers have long suspected that the mechanical forces and shear stress of blood flow could be closely-related to VWF's function.

"In some ways, like in the movie Star Wars, VWF may be considered a Jedi knight in our body that can use 'the force' to guard the bloodstream," says Timothy Springer, PhD, of Boston Children's Hospital and Harvard Medical School (HMS).

It has not been possible to witness exactly how VWF senses and harnesses these mechanical forcesuntil now.

A team in the Boston Children's Program in Cellular and Molecular Medicine and the HMS Department of Biological Chemistry and Molecular Pharmacology, co-led by Springer and Wesley P. Wong, PhD, has revealed exactly how VWF does its job.

Cutting-edge fluorescence imaging and microfluidic tools, developed by the team, allowed them to capture images of individual VWF molecules on camera while manipulating the molecules with life-like mechanical forces emulating natural blood flow.

The team's findings, published in Nature Communications, reveal that VWF undergoes a two-step, shapeshifting transformation to activate blood clotting. This transformation is triggered when VWF senses certain changes in blood flow that are indicative of injury.

The closest-ever look at blood clotting

"Under normal circumstances, VWF molecules are compact and globular in shape," says Hongxia Fu, PhD, a researcher in Springer's lab and co-first author on the paper. "But we found that whenblood flowrate increases, VWF rapidly elongates, stretching out more and more in response to higher shear stress."

However, elongating is not sufficient on its own to activateblood clotting. To safeguard against unnecessaryand potentially life threateningblood clots, it's only when the tensile forces generated in the elongated VWF hit critical levels that the shapeshifter's transformation becomes complete.

The tensile forces activate"sticky" sites along VWF, allowing it to adhere to circulating platelets, the cells that work in conjunction with VWF to clump up and stop blood loss.

Normally, the rush of blood needed to reach these critically-high tensile forces can only occur at sites of injury inside blood vessels. This specificity enables VWF to sense blood loss and activate rapidly and locally, without activating elsewhere in the body.

"If you can imagine stretching out your arms, and then opening your hands to capture platelets, that's basically what we are seeing VWF do in response to bleeding," says Wong. "It's so important that this process occurs only when and where it is needed - this two-step activation process makes that possible."

A new view on blood disease diagnostics and drugs

Yan Jiang, PhD, a postdoctoral fellow in Wong's lab, also a co-first author on the paper, says the new findings could inspire smart drugs that are designed to treat the obstructive clotting, like deep vein thrombosis, at only diseased areas of the body.

"When you're putting a generic drug into the circulatory system, it's taking effect everywhere, even in places that can cause detriment," says Jiang. "For example, anticoagulants are medically necessary in many cases to prevent blood clots from forming, but they also carry the risk of excessive bleeding. But, what if we could design a smart drug that can mimic the two-step shapeshifting of VWF and only takes effect in areas where clotting is likely to occur?"

Revealing how VWF responds to changes in flow in the highly dynamic bloodstream is a critical step to understanding the interplay between mechanical force and biology in clotting-related diseases and developing novel therapeutics.

"This experiment really represents a new platform for seeing and measuring what's happening in thebloodon a molecular level," says Wong. "Through the use of novel microfluidic technologies that allow us to mimic the body's vasculature in combination with single-molecule imaging techniques, we are finally able to capture striking images that uncover the mystery of nature's forces at work in our bodies."

Read more from the original source:

'Shapeshifter' that regulates blood clotting is visually captured for the first time - Bioscience Technology

Molecular Medicine SpA (MLM) Plunges -0.73% on Aug 24 – Key Gazette

August 24, 2017 - By Henry Gaston

Shares of Molecular Medicine SpA (BIT:MLM) last traded at 0.41, representing a move of -0.73%, or -0.003 per share, on volume of 1.19M shares. After opening the trading day at 0.42, shares of Molecular Medicine SpA traded in a close range. Molecular Medicine SpA currently has a total float of 431.45 million shares and on average sees 1.28M shares exchange hands each day. The stock now has a 52-week low of 0.31 and high of 0.64.

Italy is known worldwide not just for being a country with a rich culture and heritage but most importantly, for being a nation with a competent trade and commerce conduct. It lures Molecular Medicine SpA to its market. That being said, it is surely one of the biggest assets of the European economy.

Having been tested through the toughest of times, there is so much to learn from the economy of Italy. Through the years, Italy and its equity market in particular, has helped shape Europe as a successfully thriving region.

The Italian equity market dates back as early as the 1800s. The Borsa Italiana or Piazza Affari, the main Italian stock exchange, had been founded as one of the earliest European stock exchanges in February 1808 by Viceroy of the Napoleonic Kingdom of Italy Eugne de Beauharnais.

The Borsa Italiana boasts as one of the few stock exchanges with the longest trading hours. The pre-market session begins at 8:00 a.m. and ends at 9:00 a.m. The regular session immediately follows at 9:00 a.m. and ends at 5:30 p.m. There is also a post market session that begins at 6:00 p.m. and ends at 8:30 p.m. These long trading hours provide flexible opportunities for international investors to buy and sell stocks on and from the Borsa Italiana. This is one of the reasons that Italy has one of the most successful trade and commerce environments in the world. Many investors are looking for reliable companies like Molecular Medicine SpA there.

The FTSE Milano Italia Borsa (MIB) is the free-float market-capitalization-weighted index that monitors the 40 most actively traded stocks on the Borsa Italiana. Until June 2009 when the FTSE had started operating the FTSE MIB, the S&P had operated it as the S&P/MIB.

Roughly 80% of the overall market valuation on the Borsa Italiana is included in the FTSE MIB, making it a significant economic indicator not just in Italy but in the entire European region. The FTSE MIB is rebalanced four times a year in order to maintain clear representation of the national economy. Molecular Medicine SpA stocks are carefully checked by professionals.

The Borsa Italiana had always been operated as a public entity until it was privatized in 1998. The London Stock Exchange Group had then bought it in an all-stock transaction in 2007, consolidating the Borsa Italiana and the London Stock Exchange.

Hundreds of years after its foundation, the Borsa Italiana now has an overall market valuation of about $650 billion with over 340 stocks listed on it.

Meanwhile, the FTSE MIB had posted its all-time high of 50,108.56 points in March 2000; and its all-time low of 12,362.50 points in July 2012. The meltdown in 2012 is widely attributed to the financial crisis in Spain, which had affected other European nations; and to the heightened borrowing costs in Europe.

Investing on Borsa Italiana stocks is ideal today not just for domestic investors but also for international investors. Evidently, many investors are flocking the Italian equity market to take advantage of a compelling borrowing environment.

More notable recent Molecular Medicine SpA (BIT:MLM) news were published by: Bloomberg.com which released: Berlusconi Campaigns for No as His Top Managers Back Renzi on November 23, 2016, also Prnewswire.com with their article: DiaSorin SpA Completes Acquisition of the Focus Diagnostics Molecular and published on May 13, 2016, Sacbee.com published: Discoveries: In western Sonoma County, ferment in the finest cedar chips on February 13, 2016. More interesting news about Molecular Medicine SpA (BIT:MLM) were released by: Globenewswire.com and their article: Progenics Pharmaceuticals Announces Positive Topline Results from published on March 30, 2017 as well as Indystar.coms news article titled: The man behind the Guyer Institute with publication date: December 29, 2015.

Molecular Medicine SpA is an Italy firm engaged in the medical biotechnology sector. The company has market cap of 176.89 million EUR. The Firm is active in the research, development and clinical validation of therapies for the treatment of cancer. It currently has negative earnings. The Companys activities include identification and development of bio-pharmaceuticals reducing the tumor mass and slowing down its growth, as well as the development of selective therapies to eliminate residual tumor tissue.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

View post:

Molecular Medicine SpA (MLM) Plunges -0.73% on Aug 24 - Key Gazette

Jupiter-based Scripps researchers awarded grant to study, treat genetic disease – South Florida Business Journal


South Florida Business Journal
Jupiter-based Scripps researchers awarded grant to study, treat genetic disease
South Florida Business Journal
A division of the National Institutes of Health has awarded almost $1 million to South Florida-based researchers to develop a drug aimed at treating a genetic condition that causes tumors, severe hearing loss and impaired balance. The Scripps Research ...

View original post here:

Jupiter-based Scripps researchers awarded grant to study, treat genetic disease - South Florida Business Journal

Tudor to head medical lab program at Motlow – Elk Valley Times

Kim-Sue Tudor

Dr. Kim-Sue Tudor has been selected to lead the newly approved medical laboratory technology (MLT) program at Motlow State Community College, according to Pat Hendrix, dean of allied health.

The goal of the Smyrna campus-based program is to obtain state approval and to be positioned to attain national accreditation by the summer of 2018, when MLT classes are scheduled to begin.

Having served as both a clinician and academician, Tudor comes to Motlow State with the blended background needed to establish as well as to grow a first-class, competitive, and successful MLT program. She has worked on staff at John Hopkins University and Hospital in Baltimore, Maryland among other leading hospitals in Georgia, Tennessee, Oklahoma, Ohio, Kentucky and Virginia.

We are indeed fortunate to have Kim-Sue join the Motlow staff as program director of the MLT program, which expands the colleges allied health programs and meets a specific healthcare need in our communities, said Hendrix. The program will attract a student population that has been requesting MLT training for years. Kim-Sues well-versed, extensive background in the field will yield dividends and position the program as another leader in the allied health profession at Motlow State.

With the charge of establishing the medical laboratory technology program, I am privileged to be able to contribute to Motlows mission of promoting personal enrichment and economic and community development, Tudor said. I aspire to create and lead a nationally accredited clinical laboratory science program that features educational innovation and sophisticated contemporary laboratory technology and automation.

Tudor received a bachelors degree in biology and medical technology from James Madison University in Harrisonburg, Virginia, a certificate in medical technology from Rockingham Memorial Hospital School of Medical Technology, and a Ph.D. in pathobiology and molecular medicine from the University of Cincinnati in Cincinnati, Ohio. Additionally, Tudor has certifications and licensures from the American Society of Clinical Pathologists, National Certification Agency for Medical Laboratory Personnel, and the State of Tennessee, Division of Health.

As a clinical laboratory science educator and academic professional, Tudor has worked as a medical technologist 2, clinical laboratory scientist 3, senior research specialist, and a senior flow cytometry analyst. She most recently served as program director of the MLT program at Volunteer State Community College. She served as an assistant professor in the clinical laboratory sciences division at University of Minnesota.

Tudors most recent published works are An Introduction to Genetic Analysis: A Self-Study Unit in Molecular Biology and Molecular Diagnostic Testing and Your Immune System video in collaboration with Master Communication Group.

Tudors office is based at the Smyrna campus, MaryLou Apple Building, room 213. She can be reached at 615.220.7912 or ktudor@mscc.edu.

Read more here:

Tudor to head medical lab program at Motlow - Elk Valley Times

Mouse model of human immune system inadequate for stem cell studies – Medical Xpress

August 22, 2017 Credit: Martha Sexton/public domain

A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School of Medicine. The researchers urge further optimization of this animal model before making decisions about whether and when to begin wide-scale stem cell transplants in humans.

Known as "humanized" mice, the animals have been engineered to have a human, rather than a murine, immune system. Researchers have relied upon the animals for decades to study, among other things, the immune response to the transplantation of pancreatic islet cells for diabetes and skin grafts for burn victims.

However, the Stanford researchers found that, unlike what would occur in a human patient, the humanized mice are unable to robustly reject the transplantation of genetically mismatched human stem cells. As a result, they can't be used to study the immunosuppressive drugs that patients will likely require after transplant. The researchers conclude that the humanized mouse model is not suitable for studying the human immune response to transplanted stem cells or cells derived from them.

"In an ideal situation, these humanized mice would reject foreign stem cells just as a human patient would," said Joseph Wu, MD, PhD, director of Stanford's Cardiovascular Institute and professor of cardiovascular medicine and of radiology. "We could then test a variety of immunosuppressive drugs to learn which might work best in patients, or to screen for new drugs that could inhibit this rejection. We can't do that with these animals."

Wu shares senior authorship of the research, which will be published Aug. 22 in Cell Reports, with Dale Greiner, PhD, professor in the Program in Molecular Medicine at the University of Massachusetts Medical School, and Leonard Shultz, PhD, professor at the Jackson Laboratory. Former postdoctoral scholars Nigel Kooreman, MD, and Patricia de Almeida, PhD, and graduate student Jonathan Stack, DVM, share lead authorship of the study.

"Although these mice are fully functional in their immune response to HIV infection or after transplantation of other tissues, they are unable to completely reject the stem cells," said Kooreman. "Understanding why this is, and whether we can overcome this deficiency, is a critical step in advancing stem cell therapies in humans."

"Humanized mice are critical preclinical models in many biomedical fields helping to bring basic science into the clinic, but as this work shows, it is critical to frame the question properly," said Greiner. "Multiple laboratories remain committed to advancing our understanding and enhancing the function of engrafted human immune systems."

Greiner and Shultz helped to pioneer the use of humanized mice in the 1990s to model human diseases and they provided the mice used in the study.

Understanding stem cell transplants

The researchers were studying pluripotent stem cells, which can become any tissue in the body. They tested the animals' immune response to human embryonic stem cells, which are naturally pluripotent, and to induced pluripotent stem cells. Although iPS cells can be made from a patient's own tissues, future clinical applications will likely rely on pre-screened, FDA-approved banks of stem cell-derived products developed for specific clinical situations, such as heart muscle cells to repair tissue damaged by a heart attack, or endothelial cells to stimulate new blood vessel growth. Unlike patient-specific iPS cells, these cells would be reliable and immediately available for clinical use. But because they won't genetically match each patient, it's likely that they would be rejected without giving the recipients immunosuppressive drugs.

Humanized mice were first developed in the 1980s. Researchers genetically engineered the mice to be unable to develop their own immune system. They then used human immune and bone marrow precursor cells to reconstitute the animals' immune system. Over the years subsequent studies have shown that the human immune cells survive better when fragments of the human thymus and liver are also implanted into the animals.

Kooreman and his colleagues found that two varieties of humanized mice were unable to completely reject unrelated human embryonic stem cells or iPS cells, despite the fact that some human immune cells homed to and were active in the transplanted stem cell grafts. In some cases, the cells not only thrived, but grew rapidly to form cancers called teratomas. In contrast, mice with unaltered immune systems quickly dispatched both forms of human pluripotent stem cells.

The researchers obtained similar results when they transplanted endothelial cells derived from the pluripotent stem cells.

A new mouse model

To understand more about what was happening, Kooreman and his colleagues created a new mouse model similar to the humanized mice. Instead of reconstituting the animals' nonexistent immune systems with human cells, however, they used immune and bone marrow cells from a different strain of mice. They then performed the same set of experiments again.

Unlike the humanized mice, these new mice robustly rejected human pluripotent stem cells as well as mouse stem cells from a genetically mismatched strain of mice. In other words, their newly acquired immune systems appeared to be in much better working order.

Although more research needs to be done to identify the cause of the discrepancy between the two types of animals, the researchers speculate it may have something to do with the complexity of the immune system and the need to further optimize the humanized mouse model to perhaps include other types of cells or signaling molecules. In the meantime, they are warning other researchers of potential pitfalls in using this model to screen for immunosuppressive drugs that could be effective after human stem cell transplants.

"Many in the fields of pluripotent stem cell research and regenerative medicine are pushing the use of the humanized mice to study the human immune response," said Kooreman. "But if we start to make claims using this model, assuming that these cells won't be rejected by patients, it could be worrisome. Our work clearly shows that, although there is some human immune cell activity, these animals don't fully reconstitute the human immune system."

The researchers are hopeful that recent advances may overcome some of the current model's limitations.

"The immune system is highly complex and there still remains much we need to learn," said Shultz. "Each roadblock we identify will only serve as a landmark as we navigate the future. Already, we've seen recent improvements in humanized mouse models that foster enhancement of human immune function."

Explore further: Study provides hope for some human stem cell therapies

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:

Mouse model of human immune system inadequate for stem cell studies - Medical Xpress

Sunquest Information Systems Announces the General Availability of Sunquest Mitogen: Molecular LIMS and … – Markets Insider

TUCSON, Ariz., Aug. 22, 2017 /PRNewswire/ -- Sunquest Information Systems, Inc. announced today the general availability of Sunquest Mitogen, a laboratory information management system (LIMS) and genetic analysis software suite for molecular diagnostics and precision medicine. The comprehensive, integrated molecular and genetics laboratory solution streamlines data and processes across the wet lab and the dry lab from sample accessioning and tracking; to lab workflows, inventory and reagent management; to data generation, genetic analysis, and clinical report creation and delivery.

"Sunquest is committed to advancing technology to allow our laboratory partners to respond to market demand. As medical treatments become more precise, clinicians are looking to laboratories to support precision medicine. This requires taking on complex lab processes and delivering easy-to-understand, clinically actionable reports with short turnaround times and at lower cost," said Matt Hawkins, president/CEO of Sunquest. "The innovation embodied in Sunquest Mitogen makes this much easier."

"We wanted a platform that was paperless, cutting-edge, alive and responsive. But with many LIMS platforms we looked at, attempting to adapt them to molecular testing was like fitting a square peg into a round hole. Sunquest Mitogen is different it is designed for molecular testing," said Dr. Jason Walker, chief scientific officer at MedComp Sciences, a clinical laboratory services company and Sunquest client. "The end result is something we are truly proud of at MedComp. It is an investment we have made in laboratory quality and in our future."

"Sunquest delivers laboratory solutions that support world-class labs," Hawkins added. "Sunquest Mitogen is an innovative, comprehensive and flexible solution for laboratories to simplify and streamline extremely complicated molecular diagnostics and genetic testing processes and analysis. Sunquest Mitogen flexibly fits into existing laboratory workflows and new workflows are quick to build, which is essential in a molecular lab."

Nabil Hafez, senior director of product management for Sunquest's precision medicine solution added, "By taming the extreme complexity of molecular diagnostic laboratory processes and genetic variant analysis, we're creating the right conditions for laboratories to offer these important diagnostic tests."

Sunquest Mitogen laboratory software addresses the high complexity of sample lineage, laboratory processes, and genetic analysis for molecular diagnostics and precision medicine, which requires a laboratory platform designed from its foundation for this kind of laboratory work. In addition, Sunquest Mitogen interfaces with other clinical software, instruments, and services at the lab, and the electronic medical records used by healthcare providers.

The new solution combines the power of two key complimentary acquisitions, GeneInsight and UNIConnect, and optimizes the combined value with a set of pre-defined, out-of-the-box workflows for the LIMS and genetic analysis components.

Sunquest Mitogen: the comprehensive and configurable molecular LIMS for the wet lab

A modular, scalable, laboratory process management platform, Sunquest Mitogen supports a wide range of molecular testing requirements, from entrepreneurial molecular diagnostic companies to molecular pathology departments of major health systems. Sunquest Mitogen is a hosted, cloud-based platform accessed from a client's web browser, making for a small footprint and minimal dependency on the client's IT resources.

The molecular LIMS architecture offers rich sample tracking and deep auditing capabilities. In molecular testing, samples can move from one container type (plates, wells, vials) to another multiple times. Sunquest Mitogen tracks every step and transfer, so users can view sample path by process step, user or time frame. The information is captured and organized automatically to create a detailed audit trail and chain of custody for CAP and CLIA compliance and audits.

The Sunquest Mitogen LIMS also provides robust reagent, instrument, inventory, document, personnel and sample storage management capabilities. Users can drill down through interactive charts and graphs to individual customers, payers, and samples, and to view consumables and costs across projects and time.

Ready-made and custom laboratory workflows provided with the Sunquest Mitogen LIMS include:

Sunquest Mitogen: scalable genetic analysis software for the dry lab

Sunquest Mitogen's genetic analysis software helps clinical laboratories expand into and scale next generation sequencing (NGS) testing services for precision medicine from a single gene to a whole genome. Pathologists, data scientists, and lab directors use the Sunquest Mitogen genetic analysis software in the dry lab to bring in data from the LIMS, produce actionable reports with consistent genetic variant annotation and interpretation, and deliver to clinicians electronic medical record (EMR)-ready reports and variant data.

About 80% of each customizable report is generated automatically, reducing the time spent creating each clinically actionable genetic test report to minutes instead of hours. The reports are easy to edit and are customizable to each laboratory's needs.

The ability to tap into trusted content from well-known sources to identify clinically significant genetic variants saves time and improves report quality, and also provides information to incorporate disease, drug, and clinical trial information into the reports. Each lab can access external sources to develop its own knowledgebase and can choose to share data in real-time with other labs greatly speeding the flow of up-to-date knowledge and improving consistency and accuracy.

Monarch Initiative's ontology is among the knowledge sources to which access is provided. A collaboration of multiple organizations steeped in the advancement of genetic knowledge, the Monarch Initiative integrates biological data from multiple authoritative data sources at an unprecedented level, connecting phenotypes to genotypes across species. For example, a mutation may give rise to similar diseases in multiple species, including humans. Monarch Initiative brings this data together to help identify a patient's clinical features.

About Sunquest Information Systems

Sunquest Information Systems Inc. provides diagnostic informatics solutions to more than 1,700 laboratories. Since 1979, Sunquest has helped laboratories and healthcare organizations across the world enhance efficiency, improve patient care, and optimize financial results. Sunquest's solutions enable world-class lab capabilities, including multisite, multi-disciplinary support for complex anatomic, molecular and genetic testing, and engagement with physicians and patients outside the hospitals at the point-of-care.

Headquartered in Tucson, AZ with offices in Boston, London, Dubai, United Arab Emirates, and Bangalore, India, Sunquest is a global leader in healthcare information Technology. For more information, visit http://www.sunquestinfo.com/mitogen

Contact info: Trish Moxam Vice President, Corporate Marketing rel="nofollow">trish.moxam@sunquestinfo.com 520-237-4024

View original content:http://www.prnewswire.com/news-releases/sunquest-information-systems-announces-the-general-availability-of-sunquest-mitogen-molecular-lims-and-genetic-analysis-for-laboratories-300507515.html

SOURCE Sunquest Information Systems, Inc.

Read more here:

Sunquest Information Systems Announces the General Availability of Sunquest Mitogen: Molecular LIMS and ... - Markets Insider

Nuclear Imaging Market – Forecasts and Analysis by Technavio – Business Wire (press release)

LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global nuclear imaging market is expected to grow at a CAGR of more than 6% during the forecast period.

This research report titled Global Nuclear Imaging Market 2017-2021 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.

The global nuclear imaging market has a great potential to grow in the coming future. Currently, the nuclear imaging market is dominated by the Americas followed by EMEA and APAC. In the Americas, North America dominated the market hold the largest market share followed by Europe. The factors contributing the growth in this region are increasing the availability of nuclear imaging centers, rapid and growing geriatric population coupled with cardiac disorders, and high prevalence of cancers. Also, growing technological advances in instruments and increasing demand for non-invasive diagnostic imaging techniques contribute to the growth of the global nuclear imaging market.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavios healthcare and life sciences research analysts categorize the global nuclear imaging market into the following segments by product. They are:

Looking for more information on this market? Request a free sample report

Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Standalone PET nuclear imaging

Positron emission tomography (PET) is a functional non-invasive imaging technique, which involves the use of radioactive pharmaceuticals injected into the body (oral, inhaled or intravenously administered) that enables visualization of metabolic processes of the organs. Standalone PET systems have sensitive detector panels to capture the gamma rays which comes from the body and create a 3D computed tomography images of the tracer concentrations in the body.

According to Barath Palada, a lead medical imaging research analyst from Technavio, The standalone PET nuclear imaging used to diagnose cancers, heart diseases, endocrine, neurological and many other abnormalities in the body. PET scanners also assess cellular metabolic functions accurately which helps the doctor evaluate the functioning of the organ or tissues. PET technology can deliver high-quality images and, hence, is used for both medical and research purposes.

Standalone SPECT nuclear imaging

Single-photon emission computed tomography (SPECT) is a nuclear tomographic imaging technique that uses gamma rays to diagnose and monitor various disorders such as those of the brain, heart, and bone. A SPECT scan controls the level of biological activity to acquire 3D images from multiple angles.

SPECT nuclear imaging technique is used for various applications such as to diagnose conditions of the central nervous system, in radiosurgery, for the treatment of intracranial tumors, arteriovenous malformations, and other surgical procedures. The adoption rate for SPECT is increasing, due to the high cost of PET scanners, adds Barath.

Hybrid nuclear imaging

Hybrid nuclear imaging is an excellent diagnostic tool in the modern-day medicine used for multiple therapeutic applications. Hybrid nuclear imaging involves the fusion of different diagnostic imaging products such as PET/CT, PET/MRI, PET/SPECT, SPECT/CT, and SPECT/MRI which allows correlation between anatomical and functional imaging.

SPECT/CT hybrid nuclear imaging has proven valuable for oncology. These hybrid nuclear imaging modalities have potential to aid the develop personalized molecular medicine. These technologies will aid in detecting and evaluating various disorders such as cardiology, oncology, and neurology.

The top vendors highlighted by Technavios research analysts in this report are:

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Read more:

Nuclear Imaging Market - Forecasts and Analysis by Technavio - Business Wire (press release)

New method for the 3D printing of living tissues | Scientist Live – Scientist Live

Scientists at the University of Oxford have developed a new method to 3D-print laboratory- grown cells to form living structures.

The approach could revolutionise regenerative medicine, enabling the production of complex tissues and cartilage that would potentially support, repair or augment diseased and damaged areas of the body.

In research published in the journal Scientific Reports, an interdisciplinary team from the Department of Chemistry and the Department of Physiology, Anatomy and Genetics at Oxford and the Centre for Molecular Medicine at Bristol, demonstrated how a range of human and animal cells can be printed into high-resolution tissue constructs.

Interest in 3D printing living tissues has grown in recent years, but, developing an effective way to use the technology has been difficult, particularly since accurately controlling the position of cells in 3D is hard to do.

They often move within printed structures and the soft scaffolding printed to support the cells can collapse on itself.

As a result, it remains a challenge to print high-resolution living tissues. But, led by Professor Hagan Bayley, Professor of Chemical Biology in Oxfords Department of Chemistry, the team devised a way to produce tissues in self-contained cells that support the structures to keep their shape.

The cells were contained within protective nanolitre droplets wrapped in a lipid coating that could be assembled, layer-by-layer, into living structures.

Producing printed tissues in this way improves the survival rate of the individual cells, and allowed the team to improve on current techniques by building each tissue one drop at a time to a more favourable resolution.

To be useful, artificial tissues need to be able to mimic the behaviours and functions of the human body. The method enables the fabrication of patterned cellular constructs, which, once fully grown, mimic or potentially enhance natural tissues.

Dr Alexander Graham, lead author and 3D Bioprinting Scientist at OxSyBio (Oxford Synthetic Biology), said: We were aiming to fabricate three-dimensional living tissues that could display the basic behaviours and physiology found in natural organisms. To date, there are limited examples of printed tissues, which have the complex cellular architecture of native tissues. Hence, we focused on designing a high-resolution cell printing platform, from relatively inexpensive components, that could be used to reproducibly produce artificial tissues with appropriate complexity from a range of cells including stem cells.

The researchers hope that, with further development, the materials could have a wide impact on healthcare worldwide. Potential applications include shaping reproducible human tissue models that could take away the need for clinical animal testing.

The team completed their research last year, and have since taken steps towards commercialising the technique and making it more widely available. In January 2016, OxSyBio officially spun-out from the Bayley Lab. The company aims to commercialise the technique for industrial and biomedical purposes.

Over the coming months they will work to develop new complementary printing techniques, that allow the use of a wider range of living and hybrid materials, to produce tissues at industrial scale. Dr Sam Olof, Chief Technology Officer at OxSyBio, said: There are many potential applications for bioprinting and we believe it will be possible to create personalised treatments by using cells sourced from patients to mimic or enhance natural tissue function. In the future, 3D bio-printed tissues maybe also be used for diagnostic applications for example, for drug or toxin screening.

Dr Adam Perriman from the University of Bristols School of Cellular and Molecular Medicine, added: The bioprinting approach developed with Oxford University is very exciting, as the cellular constructs can be printed efficiently at extremely high resolution with very little waste. The ability to 3D print with adult stem cells and still have them differentiate was remarkable, and really shows the potential of this new methodology to impact regenerative medicine globally

The full citation for the paper is High-resolution patterned cellular constructs by droplet-based 3D printingA.D. Graham et. al. Scientific Reports 7, Article number: 7004 (2017).

More here:

New method for the 3D printing of living tissues | Scientist Live - Scientist Live

Bio-inspired Materials Give Boost to Regenerative Medicine – Bioscience Technology

What if one day, we could teach our bodies to self-heal like a lizards tail, and make severe injury or disease no more threatening than a paper cut?

Or heal tissues by coaxing cells to multiply, repair or replace damaged regions in loved ones whose lives have been ravaged by stroke, Alzheimers or Parkinsons disease?

Such is the vision, promise and excitement in the burgeoning field of regenerative medicine, now a major ASU initiative to boost 21st-century medical research discoveries.

ASU Biodesign Institute researcher Nick Stephanopoulos is one of several rising stars in regenerative medicine. In 2015, Stephanopoulos, along with Alex Green and Jeremy Mills, were recruited to the Biodesign Institutes Center for Molecular Design and Biomimetics (CMDB), directed by Hao Yan, a world-recognized leader in nanotechnology.

One of the things that that attracted me most to the ASU and the Biodesign CMDB was Haos vision to build a group of researchers that use biological molecules and design principles to make new materials that can mimic, and one day surpass, the most complex functions of biology, Stephanopoulos said.

I have always been fascinated by using biological building blocks like proteins, peptides and DNA to construct self-assembled structures, devices and materials, and the interdisciplinary and highly collaborative team in the CMDB is the ideal place to put this vision into practice.

Yans research center uses DNA and other basic building blocks to build their nanotechnology structures only at a scale 1,000 times smaller than the width of a human hair.

Theyve already used nanotechnology to build containers to specially deliver drugs to tissues, build robots to navigate a maze or nanowires for electronics.

To build a manufacturing industry at that tiny scale, their bricks and mortar use a colorful assortment of molecular Legos. Just combine the ingredients, and these building blocks can self-assemble in a seemingly infinite number of ways only limited by the laws of chemistry and physics and the creative imaginations of these budding nano-architects.

Learning from nature

The goal of the Center for Molecular Design and Biomimetics is to usenatures design rulesas an inspiration in advancing biomedical, energy and electronics innovation throughself-assembling moleculesto create intelligent materials for better component control and for synthesis intohigher-order systems, said Yan, who also holds the Milton Glick Chair in Chemistry and Biochemistry.

Prior to joining ASU, Stephanopoulos trained with experts in biological nanomaterials, obtaining his doctorate with the University of California Berkeleys Matthew Francis, and completed postdoctoral studies with Samuel Stupp at Northwestern University. At Northwestern, he was part of a team that developed a new category of quilt-like, self-assembling peptide and peptide-DNA biomaterials for regenerative medicine, with an emphasis in neural tissue engineering.

Weve learned from nature many of the rules behind materials that can self-assemble. Some of the most elegant complex and adaptable examples of self-assembly are found in biological systems, Stephanopoulos said.

Because they are built from the ground-up using molecules found in nature, these materials are also biocompatible and biodegradable, opening up brand-new vistas for regenerative medicine.

Stephanopoulos tool kit includes using proteins, peptides, lipids and nucleic acids like DNA that have a rich biological lexicon of self-assembly.

DNA possesses great potential for the construction of self-assembled biomaterials due to its highly programmable nature; any two strands of DNA can be coaxed to assemble to make nanoscale constructs and devices with exquisite precision and complexity, Stephanopoulos said.

Proof all in the design

During his time at Northwestern, Stephanopoulos worked on a number of projects and developed proof-of-concept technologies for spinal cord injury, bone regeneration and nanomaterials to guide stem cell differentiation.

Now, more recently, in a new studyin Nature Communications, Stephanopoulos and his colleague Ronit Freeman in the Stupp laboratory successfully demonstrated the ability to dynamically control the environment around stem cells, to guide their behavior in new and powerful ways.

In the new technology, materials are first chemically decorated with different strands of DNA, each with a unique code for a different signal to cells.

To activate signals within the cells, soluble molecules containing complementary DNA strands are coupled to short protein fragments, called peptides, and added to the material to create DNA double helices displaying the signal.

By adding a few drops of the DNA-peptide mixture, the material effectively gives a green light to stem cells to reproduce and generate more cells. In order to dynamically tune the signal presentation, the surface is exposed to a soluble single-stranded DNA molecule designed to grab the signal-containing strand of the duplex and form a new DNA double helix, displacing the old signal from the surface.

This new duplex can then be washed away, turning the signal off. To turn the signal back on, all that is needed is to now introduce a new copy of single-stranded DNA bearing a signal that will reattach to the materials surface.

One of the findings of this work is the possibility of using the synthetic material to signal neural stem cells to proliferate, then at a specific time selected by the scientist, trigger their differentiation into neurons for a while, before returning the stem cells to a proliferative state on demand.

One potential use of the new technology to manipulate cells could help cure a patient with neurodegenerative conditions like Parkinsons disease.

The patients own skin cells could be converted to stem cells using existing techniques. The new technology could help expand the newly converted stem cells back in the lab and then direct their growth into specific dopamine-producing neurons before transplantation back to the patient.

People would love to have cell therapies that utilize stem cells derived from their own bodies to regenerate tissue, Stupp said. In principle, this will eventually be possible, but one needs procedures that are effective at expanding and differentiating cells in order to do so. Our technology does that.

In the future, it might be possible to perform this process entirely within the body. The stem cells would be implanted in the clinic, encapsulated in the type of material described in the new work, and injected into a particular spot. Then the soluble peptide-DNA molecules would be given to the patient to bind to the material and manipulate the proliferation and differentiation of transplanted cells.

Scaling the barriers

One of the future challenges in this area will be to develop materials that can respond better to external stimuli and reconfigure their physical or chemical properties accordingly.

Biological systems are complex, and treating injury or disease will in many cases necessitate a material that can mimic the complex spatiotemporal dynamics of the tissues they are used to treat, Stephanopoulos said.

It is likely that hybrid systems that combine multiple chemical elements will be necessary; some components may provide structure, others biological signaling and yet others a switchable element to imbue dynamic ability to the material.

A second challenge, and opportunity, for regenerative medicine lies in creating nanostructures that can organize material across multiple length scales. Biological systems themselves are hierarchically organized: from molecules to cells to tissues, and up to entire organisms.

Consider that for all of us, life starts simple, with just a single cell. By the time we reach adulthood, every adult human body is its own universe of cells, with recent estimates of 37 trillion or so. The human brain alone has 100 billion cells or about the same number of cells as stars in the Milky Way galaxy.

But over the course of a life, or by disease, whole constellations of cells are lost due to the ravages of time or the genetic blueprints going awry.

Collaborative DNA

To overcome these obstacles, much more research funding and recruitment of additional talent to ASU will be needed to build the necessary regenerative medicine workforce.

Last year, Stephanopoulos research received a boost with funding from the U.S. Air Forces Young Investigator Research Program (YIP).

The Air Force Office of Scientific ResearchYIP award will facilitate Nicks research agenda in this direction, and is a significant recognition of his creativity and track record at the early stage of his careers, Yan said.

Theyll need this and more to meet the ultimate challenge in the development of self-assembled biomaterials and translation to clinical applications.

Buoyed by the funding, during the next research steps, Stephanopoulos wants to further expand horizons with collaborations from other ASU colleagues to take his research teams efforts one step closer to the clinic.

ASU and the Biodesign Institute also offer world-class researchers in engineering, physics and biology for collaborations, not to mention close ties with the Mayo Clinic or a number of Phoenix-area institutes so we can translate our materials to medically relevant applications, Stephanopoulos said.

There is growing recognition that regenerative medicine in the Valley could be a win-win for the area, in delivering new cures to patients and building, person by person, a brand-new medicinal manufacturing industry.

Stephanopoulos recent research was carried out at Stupps Northwesterns Simpson Querrey Institute for BioNanotechnology. The National Institute of Dental and Craniofacial Research of the National Institutes of Health (grant 5R01DE015920) provided funding for biological experiments, and the U.S. Department of Energy, Office of Science, Basic Energy Sciences provided funding for the development of the new materials (grants DE-FG01-00ER45810 and DE-SC0000989 supporting an Energy Frontiers Research Center on Bio-Inspired Energy Science (CBES)).

The paper is titled Instructing cells with programmable peptide DNA hybrids. Samuel I. Stupp is the senior author of the paper, and post-doctoral fellows Ronit Freeman and Nicholas Stephanopoulos are primary authors.

Read more here:

Bio-inspired Materials Give Boost to Regenerative Medicine - Bioscience Technology